Oculis Holding: Study Setback For Eye Drop Therapy Suggests Hold Rating
Source: SeekingAlpha
2026-06-02 10:16:39 ET
Oculis Investment Overview
The stock of Oculis Holding AG ( OCS ), a Zug, Switzerland headquartered biotech focused on the treatment of neuro-ophthalmic and ophthalmic diseases, was in freefall yesterday, dropping >35% for the day, from ~$23 per share to $15 per share, as the market digested topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in patients with diabetic macular edema ("DME"), released late Friday....
Read the full article on Seeking Alpha
For further details see:
Oculis Holding: Study Setback For Eye Drop Therapy Suggests Hold Rating
Oculis Holding AG
NASDAQ: OCS
OCS Trading
-0.23% G/L:
$10.795 Last:
526,254 Volume:
$10.97 Open:
OCS Latest News
June 09, 2026 04:00:00 am
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
June 08, 2026 03:25:22 pm
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
June 08, 2026 12:08:00 am
Lost Money on Oculis Holding AG (OCS)? Contact Levi & Korsinsky About Investigation
OCS Stock Data
$1,527,387,432
49,696,926
N/A
16
N/A
Biotechnology & Life Sciences
Healthcare
CH
